Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization.

ACEi, angiotensin-converting enzyme inhibitor ARB, angiotensin receptor blocker ARNI, angiotensin receptor neprilysin inhibitor ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness HF, heart failure IIT, intravenous inotropic therapy IQR, interquartile range VAD, ventricular assist device

Journal

Mayo Clinic proceedings. Innovations, quality & outcomes
ISSN: 2542-4548
Titre abrégé: Mayo Clin Proc Innov Qual Outcomes
Pays: Netherlands
ID NLM: 101728275

Informations de publication

Date de publication:
Oct 2020
Historique:
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 10 2020
Statut: epublish

Résumé

To describe the intent and early outcomes of elective inotrope use during heart failure hospitalization. A prospective multisite design was used to collect data for hemodynamically stable patients started electively on inotrope therapy between January 1 and August 31, 2018. We prospectively recorded data when intravenous inotropic therapy was initiated, including survey of the attending cardiologists regarding expectations for the clinical course. Patients were followed up for events through hospital discharge and an additional survey was administered at the end of hospitalization. For the 92 patients enrolled, average age was 60 years and ejection fraction was 24%±12%. At the time of inotrope initiation, attending heart failure cardiologists predicted that 50% (n=46) of the patients had a "high or very high" likelihood of becoming dependent on intravenous inotropic therapy and 58% (n=53) had a "high" likelihood of death, transplant, or durable ventricular assist device placement within the next 6 months. Provider predictions regarding death/hospice or need for continued home infusions were accurate only 51% (47 of 92) of the time. Only half the patients (n=47) had goals-of-care conversations before inotrope treatment initiation. More than half the patients (51 of 92) electively started on inotrope treatment without present or imminent cardiogenic shock ultimately required home inotrope therapy, died during admission, or were discharged with hospice. Heart failure clinicians could not reliably identify those patients at the time of inotrope therapy initiation and goals-of-care discussions were not frequently performed.

Identifiants

pubmed: 33083701
doi: 10.1016/j.mayocpiqo.2020.05.007
pii: S2542-4548(20)30099-0
pmc: PMC7557209
doi:

Types de publication

Journal Article

Langues

eng

Pagination

529-536

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL138260
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL142835
Pays : United States
Organisme : NHLBI NIH HHS
ID : U10 HL110337
Pays : United States

Informations de copyright

© 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.

Références

J Card Fail. 2017 Oct;23(10):770-774
pubmed: 28689765
Am Heart J. 2007 Jan;153(1):98-104
pubmed: 17174645
Curr Cardiol Rev. 2015;11(1):63-72
pubmed: 24251460
Resuscitation. 2015 Jul;92:14-8
pubmed: 25891959
Circ Heart Fail. 2014 Mar 1;7(2):251-60
pubmed: 24488983
Heart Lung. 2008 May-Jun;37(3):173-8
pubmed: 18482628
Heart Fail Clin. 2018 Oct;14(4):601-616
pubmed: 30266368
Circ Heart Fail. 2015 Sep;8(5):880-6
pubmed: 26179184
Eur J Heart Fail. 2018 Feb;20(2):332-341
pubmed: 28990358
Int J Gen Med. 2014 May 20;7:237-51
pubmed: 24899821
J Card Fail. 2014 Aug;20(8):593-601
pubmed: 24879975
Am Heart J. 2015 Dec;170(6):1124-32
pubmed: 26678634
J Clin Med. 2018 Oct 18;7(10):
pubmed: 30340408

Auteurs

David Snipelisky (D)

Division of Advanced Heart Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Marat Fudim (M)

Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.

Antonio Perez (A)

Section of Advanced Heart Failure and Transplant Cardiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.

Matthew Nayor (M)

Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Natasha M Lever (NM)

Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

David S Raymer (DS)

Division of Cardiology, University of Colorado School of Medicine, Aurora.

Andrew N Rosenbaum (AN)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Omar AbouEzzeddine (O)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Adrian F Hernandez (AF)

Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.

Lynne Warner Stevenson (LW)

Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN.

Lauren G Gilstrap (LG)

Dartmouth-Hitchcock Medical Center, Heart and Vascular Center, Lebanon, NH.
The Dartmouth Institute, Geisel School of Medicine at Dartmouth, Lebanon, NH.

Classifications MeSH